QurAlis Announces Exclusive License on Novel Mechanism for Fragile X Syndrome (FXS) to Enable Development of First Potential Disease-Modifying Therapy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 15, 2025--
QurAlis Corporation ('QurAlis'), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced it has entered into an exclusive license agreement with UMass Chan Medical School ('UMass Chan') on a novel RNA-targeted mechanism confirmed to restore functional protein for Fragile X syndrome (FXS).
Fragile X syndrome is the leading inherited form of intellectual disability and the most common single genetic cause of autism. It is a genetic condition caused by a mutation of a single gene – Fragile X messenger ribonucleoprotein 1 (FMR1) – on the X chromosome. This mutation of FMR1 causes a range of developmental problems including learning disabilities, behavioral challenges, and cognitive impairment.
QurAlis' exclusive license agreement is a result of its 2024 partnership and collaboration with UMass Chan to explore the biology of FXS to determine and confirm relevant targets that could enable antisense oligonucleotide (ASO)-mediated correction for FXS. QurAlis leveraged its deep understanding, knowledge and expertise in developing ASOs as part of the collaboration. QurAlis confirmed the findings from the original publication of the UMass Chan researchers and is advancing FMR1 as a precision medicine target in up to 80 percent of FXS patients. The mis-spliced form of FMR1, designated as FMR1-217, is widely expressed throughout cortical brain areas affected in FXS and can be measured in blood and cerebrospinal fluid. Preliminary data suggest biomarker feasibility to detect mis-splicing of FMR1 in patients with FXS.
'FXS is a devastating neurodevelopmental disorder with no effective disease-modifying therapies available. Our initial partnership with UMass Chan confirmed that FMR1-217 is a validated genetic target for FXS,' said Kasper Roet, Ph.D., chief executive officer and co-founder of QurAlis. 'This groundbreaking discovery of a novel RNA-targeted mechanism to restore functional protein for FXS and the feasibility of a biomarker to detect mis-splicing of FMR1 in FXS patients opens up a completely new type of therapeutic approach through splice correction. We look forward to applying QurAlis' FlexASO® platform and deep knowledge and expertise of ASO splicing targets toward having a candidate nominated for IND-enabling studies in the near future, so that we can bring a potential new precision medicine option to patients.'
Joel Richter, Ph.D., the Arthur F. Koskinas Chair in Neuroscience and professor of molecular medicine at UMass Chan, and colleagues Sneha Shah, Ph.D., and Jonathan K. Watts, Ph.D., together with Elizabeth Berry-Kravis, M.D., Ph.D., at Rush University Medical Center, have shown that aberrant alternative splicing, or mis-splicing, of messenger RNA (mRNA) plays a fundamental role in FXS. In a seminal publication by the group, it was revealed that in FXS patients, FMR1 mRNA is still being expressed, but is mis-spliced, comprising a short, truncated alternative mRNA variant called FMR1-217 which results in non-functional FMRP protein expression. Working with patient-derived cells, Dr. Richter's lab and Dr. Berry-Kravis initially demonstrated that ASOs can successfully inhibit the mis-splicing, reduce expression of FMR1-217, rescue proper FMR1 mRNA, and restore FMRP protein expression.
'This is a meaningful step in the process of taking basic biological discoveries and turning them into practical therapies that can benefit patients in the clinic,' said Dr. Richter. 'QurAlis' platform and expertise in neurodegenerative disorders are industry leading and well positioned to address the mis-splicing of FMR1 RNA and restore functional FMRP protein expression. This partnership has not only validated our years-long research but also has resulted in the confirmation of a novel target for FXS, which we hope will lead to much-needed treatment options for FXS patients and their families.'
Dr. Berry-Kravis added, 'I am very excited that we will be able to continue development of this potential genetically based disease-modifying FMRP-restoring therapy that is expected to have a major impact on the FXS field and the spectrum of treatment options available to improve function in people with FXS.'
An orphan disease, FXS affects approximately 87,000 individuals in the U.S. alone – one in 4,000 men and one in 6,000 women. Though FXS occurs in both genders, males are more frequently affected than females, and generally with greater severity. In addition to intellectual disability, FXS patients endure a wide range of disabling symptoms including severe anxiety, social aversion, hyperactivity and attention deficit, sensory hypersensitivity, aggression, developmental seizures, and others. There are no effective disease-modifying therapies currently available for FXS.
ASOs are short, engineered single-stranded DNA/RNA molecules that can selectively bind RNA to regulate its expression in the cell. ASO technology has been leading in the field of protein regulation and has since allowed us to develop treatments for neurodegenerative disease by changing the expression of genes connected to the disease.
QurAlis' FlexASO® platform was developed to generate splice-switching ASOs with improved potency, increased therapeutic index and improved bio-distribution. This bespoke platform has the potential to tackle the spectrum of neurodegenerative and neurological diseases.
About QurAlis Corporation
At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit www.quralis.com or follow us on X @QurAlisCo or LinkedIn.
View source version on businesswire.com:https://www.businesswire.com/news/home/20250515683206/en/
CONTACT: Kathy Vincent
[email protected]
310-403-8951
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS
INDUSTRY KEYWORD: RESEARCH NEUROLOGY GENETICS BIOTECHNOLOGY HEALTH UNIVERSITY PHARMACEUTICAL SCIENCE EDUCATION
SOURCE: QurAlis Corporation
Copyright Business Wire 2025.
PUB: 05/15/2025 07:45 AM/DISC: 05/15/2025 07:44 AM
http://www.businesswire.com/news/home/20250515683206/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 days ago
- Yahoo
QurAlis Announces New Global Headquarters
30,000 square foot state-of-the-art office suite, lab, and research facility doubles QurAlis' footprint in Cambridge's vibrant Alewife Biotech Park CAMBRIDGE, Mass., June 18, 2025--(BUSINESS WIRE)--QurAlis Corporation ("QurAlis"), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced the opening of its new global corporate headquarters in Cambridge, MA. The company's new 30,000 square foot state-of-the-art research facility and office space located at 35 Cambridgepark Drive ("35 CPD"), doubles QurAlis' footprint in the heart of Cambridge's vibrant Alewife Biotech Park. "Maintaining our corporate headquarters in Cambridge positions us at the heart of a thriving biotechnology hub with world-class talent and leading research institutions," said Jason Brown, MBA, chief financial officer at QurAlis. "The facility at Alewife allowed us to expand our R&D footprint, lab capacity, and office space to support QurAlis' growth and enhance our leading precision medicine portfolio and platform capabilities. Our new headquarters provides our employees with a high-tech work environment conducive to collaboration and innovation with improved space and amenities. The space will continue to foster our mission-driven culture committed to discovering and developing medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases." QurAlis and its landlord, Healthpeak, fully built out and furnished QurAlis' lab and office suite prior to occupancy. QurAlis' new headquarters offers a larger space with enhanced lab and discovery resources and a 5,000 square foot conferencing space for meeting and collaboration. More than one-third of the new facility is dedicated to a state-of-the-art 11,000 square foot lab with an expansive tissue culture suite and addition of an onsite antisense oligonucleotide (ASO) chemistry manufacturing lab to support programs utilizing QurAlis' FlexASO® technology platform. FlexASO® was developed to generate splice-switching ASOs with improved potency, increased therapeutic index and improved bio-distribution. This bespoke platform has the potential to tackle the spectrum of neurodegenerative and neurological diseases. "Healthpeak welcomes QurAlis to 35 Cambridgepark Drive," said Scott Bohn, chief development officer and head of lab at Healthpeak. "QurAlis' need for Class A lab space to progress their groundbreaking neuroscience work aligned seamlessly with our purpose-built life science campus, offering state-of-the-art amenities, a sustainable LEED Gold design, and unbeatable proximity to Alewife Station – an ideal environment for QurAlis' continued innovation and growth." Part of a 450,000 square foot RSF, three-building campus, 35 CPD is a LEED Gold 224,000 square foot RSF purpose-built life science building strategically located in West Cambridge directly across from the Alewife MBTA Station (Red line), at the end of Massachusetts Route 2, on Minuteman bike path and walkable to the Fresh Pond Reservation. 35 CPD, with attached garage, provides ample tenant amenities in the building including a Craft Food Hall, exclusive fitness center, private shower and locker rooms, secure bike room, client lounge, and activated outdoor spaces. QurAlis was represented in their search and lease negotiations by Carolyn Wheatley and Marc Consalvi at JLL. About QurAlis Corporation At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit or follow us on X @QurAlisCo or LinkedIn. View source version on Contacts Kathy 310-403-8951
Business Wire
5 days ago
- Business Wire
QurAlis Announces New Global Headquarters
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- QurAlis Corporation ('QurAlis'), a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced the opening of its new global corporate headquarters in Cambridge, MA. The company's new 30,000 square foot state-of-the-art research facility and office space located at 35 Cambridgepark Drive ('35 CPD'), doubles QurAlis' footprint in the heart of Cambridge's vibrant Alewife Biotech Park. 'Maintaining our corporate headquarters in Cambridge positions us at the heart of a thriving biotechnology hub with world-class talent and leading research institutions,' said Jason Brown, MBA, chief financial officer at QurAlis. 'The facility at Alewife allowed us to expand our R&D footprint, lab capacity, and office space to support QurAlis' growth and enhance our leading precision medicine portfolio and platform capabilities. Our new headquarters provides our employees with a high-tech work environment conducive to collaboration and innovation with improved space and amenities. The space will continue to foster our mission-driven culture committed to discovering and developing medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases.' QurAlis and its landlord, Healthpeak, fully built out and furnished QurAlis' lab and office suite prior to occupancy. QurAlis' new headquarters offers a larger space with enhanced lab and discovery resources and a 5,000 square foot conferencing space for meeting and collaboration. More than one-third of the new facility is dedicated to a state-of-the-art 11,000 square foot lab with an expansive tissue culture suite and addition of an onsite antisense oligonucleotide (ASO) chemistry manufacturing lab to support programs utilizing QurAlis' FlexASO® technology platform. FlexASO® was developed to generate splice-switching ASOs with improved potency, increased therapeutic index and improved bio-distribution. This bespoke platform has the potential to tackle the spectrum of neurodegenerative and neurological diseases. 'Healthpeak welcomes QurAlis to 35 Cambridgepark Drive,' said Scott Bohn, chief development officer and head of lab at Healthpeak. 'QurAlis' need for Class A lab space to progress their groundbreaking neuroscience work aligned seamlessly with our purpose-built life science campus, offering state-of-the-art amenities, a sustainable LEED Gold design, and unbeatable proximity to Alewife Station – an ideal environment for QurAlis' continued innovation and growth.' Part of a 450,000 square foot RSF, three-building campus, 35 CPD is a LEED Gold 224,000 square foot RSF purpose-built life science building strategically located in West Cambridge directly across from the Alewife MBTA Station (Red line), at the end of Massachusetts Route 2, on Minuteman bike path and walkable to the Fresh Pond Reservation. 35 CPD, with attached garage, provides ample tenant amenities in the building including a Craft Food Hall, exclusive fitness center, private shower and locker rooms, secure bike room, client lounge, and activated outdoor spaces. QurAlis was represented in their search and lease negotiations by Carolyn Wheatley and Marc Consalvi at JLL. About QurAlis Corporation At QurAlis, we are neuro pioneers on a quest to cure, boldly seeking to translate scientific breakthroughs into powerful precision medicines. We work collaboratively with a relentless pursuit of knowledge, precise attention to craft, and compassion to discover and develop medicines that have the potential to transform the lives of people living with neurodegenerative and neurological diseases. QurAlis is the leader in development of precision therapies for amyotrophic lateral sclerosis (ALS). In addition to ALS, QurAlis is advancing a robust precision medicine pipeline to bring effective disease-modifying therapeutics to patients suffering from severe diseases defined by genetics and clinical biomarkers. For more information, please visit or follow us on X @QurAlisCo or LinkedIn.
Yahoo
5 days ago
- Yahoo
Why the UK's AIM is struggling 30 years on
The UK's alternative investment market (AIM) has seen some major successes since its inception 30 years ago but has struggled to attract and retain companies in recent years. Launched on 19 June 1995, AIM was set up to help smaller and high-growth companies get more access to capital. When it started out, the UK's junior market comprised of just 10 companies, with a total market valuation of £82m. Eleven of the companies that joined AIM in its first six months of existence are still on the UK stock market today and eight of those companies are still on the junior market today, according to AJ Bell (AJB.L). Since launch, AIM has helped more than 4,000 companies raise nearly £136bn. Well-known companies that started out on AIM include travel company Jet2 (JET2.L), online retailer ASOS (ASC.L) and drink mixer producer Fevertree (FEVR.L). While AIM has produced a number of successes, it has also had its fair share of failures. That includes "cash shell" Langbar International, which claimed to have £370m in bank deposits but collapsed in 2005 after discovering these funds were non-existent. Another high-profile example was the collapse of cafe chain Patisserie Valerie in 2019 on the back of an accounting scandal. Such disasters have led to AIM being described as the "Wild West", though it is said to be the most active growth market in Europe, with 45% of the capital raised on European growth markets over the past five years raised on AIM, according to the London Stock Exchange (LSE). Read more: Bank of England expected to hold interest rates as oil prices rise and UK growth falters In addition, an analysis conducted by Grant Thornton found that, in 2023, AIM companies contributed £68bn in gross value added to the UK economy and supported more than 770,000 jobs. Even so, AIM has had a challenging time in recent years and research has suggested that its troubles are set to continue. According to investment bank Peel Hunt (PEEL.L) and Aberdeen Investments, AIM is set to shrink by a fifth this year, as 61 companies representing £12.3bn of market capitalisation have announced plans to leave the junior market — either to move to the main market, to delist or because they've been subject to mergers and acquisitions (M&A). If all of these moves go ahead, AIM is set to shrink by 20%. 'AIM was once a thriving market, but it has been brutally knocked back by outflows in recent times," said Abby Glennie, co-manager of the Abrdn UK Smaller Companies Fund and the Abrdn UK Smaller Companies Growth Trust plc (AUSC.L). "As a result, we're seeing many of the biggest and best AIM companies moving to a main market listing." She added: "Eventually we will be left with a tiny, illiquid market. That's fine for small, individual investors but will make it very hard to get large-scale institutional money into the growth companies of tomorrow. "In that scenario, we need to be asking: how are we going to nurture the next generation of big UK companies?" With that in mind, experts shared why AIM is struggling and what could be done to help revive the junior market and resolve these issues. Jason Hollands, managing director at Bestinvest by Evelyn Partners, said that the sharp decline in companies on AIM largely "reflects a wider malaise facing European markets for small and medium sized growth stocks in recent years, as well amplifying the broader headwinds 'unloved' UK equities have faced." "Let's not forget that there has been a dearth of IPOs on the London Stock Exchange's main market too in recent years, with a steady stream of UK companies moving their listings overseas to markets like NASDAQ (^IXIC) and the NYSE where they can command higher valuations due to deeper pools of capital," he said. Hollands added that there have also been a number of public-to-private transactions by private equity firms, which are able to pick up UK-listed businesses on low valuations. "AIM has been at the sharp end of these trends, magnifying the effect given the lack of investor appetite for small, illiquid UK companies amid an environment where passives have grown in popularity," he said. Hollands explained that tracker funds don't touch very small companies, so the trend towards index funds "sucked away capital from this part of the marked as actively managed funds have battled relentless outflows". Instead, he said that the focus has been on a relatively small group of mega-cap growth US stocks — the "Magnificent 7", which is made up of Nvidia (NVDA), Apple (AAPL), Microsoft (MSFT), Alphabet (GOOGL, GOOG), Tesla (TSLA), Amazon (AMZN) and Meta (META). In addition, Hollands said that smaller companies have had to contend with the impact of the pandemic, the cost of living crisis, along with increases in financing costs as interest rates and bond yields rose. Stocks: Create your watchlist and portfolio Nicholas Hyett, investment manager at Wealth Club, said that AIM's "recent struggles are due in part to powerful macro-economic trends affecting public markets all over the world, however they've been compounded by a series of unfortunate own goals." Firstly, he highlighted that the rise of venture capital and private equity has meant that public markets are playing a smaller part in fundraising globally. He pointed to data from law firm White & Case, which showed that initial public offerings raised $126bn in 2024 — a marginal increase on 2023, though that is well below the $211bn raised in 2018. "Companies just don't want to list on stock markets to raise money any more," said Hyett. "Staying private is lower cost and significantly less hassle than accepting the scrutiny that comes from being a public company." In addition, Hyett said AIM had also struggled with a number of "political own goals — most notably around the inheritance tax (IHT) benefits associated with AIM companies." "IHT relief has been a key driver of AIM ownership — creating a reason for individual investors to hold shares in AIM listed companies that they might not otherwise consider — providing a stable investor base that might not otherwise invest in smaller UK companies," he explained. Read more: What you need to know about UK's private stock market Pisces Historically, if investors held AIM shares for at least two years at the time of death, they would be exempt from IHT because they qualified for business property relief. However, changes to IHT in the autumn budget meant that the rate of relief was halved from 100% to 50%, meant that AIM holdings will be subject to 20% tax for those with estates above their nil-rate allowances. Bestinvest's Hollands said: "While this was not the worst outcome, it has reduced the attraction and the recent leaking of a memo of tax proposals by [deputy prime minister] Angela Rayner, included scrapping all IHT relief on AIM, will renew speculation at a time when concerns are mounting that the chancellor will need to find further tax raising measures in her next budget." Indeed, Susannah Streeter, head of money and markets at Hargreaves Lansdown, said that "perception can often count when it comes to interest in certain sectors, and with this tax-benefit changing, it could still mean more investors will steer clear from these riskier investments." "With inflation creeping back upwards again and the UK economy sluggish, confidence doesn't look set to return to the market anytime soon and depressed valuations are likely to mean overseas buyers will be circling AIM quoted firms this year," she said." Bestinvest's Hollands said that one potential "ray of sunshine" could be the Mansion House Accord, which was a government agreement with the UK's largest workplace pension schemes to invest 10% into private markets by 2030, at least half of which has to be in the UK. "One can only hope that some of this might eventually find its way into AIM companies, but a lot more could be done to revitalise the market, including beefing up VCT income tax reliefs to at least 40% and quashing speculation of tampering with IHT reliefs again," he said. Stocks: Create your watchlist and portfolio Wealth Club's Hyett said that uncertainty over IHT relief "needs to be resolved and as soon as possible". "While the uncertainty remains, the flow of money into AIM will be stifled and the government risks slowly throttling the UK's growth market," he said. "Longer term, AIM faces the same challenges as the wider stock market. Steps need to be taken to encourage UK investors, including pension funds, to put money into UK companies if you want to revitalise the UK stock market." Read more: This under-claimed benefit could help boost your pension Average UK house asking price drops by more than £1,000 Why you can trust an 18-year old with their junior ISA – and how to create one
